Director of Global Market Access Strategy
Illumina
Director of Global Market Access Strategy
Illumina
Develops sequencing platforms and consumables
Position Summary:
At Illumina, we are advancing the future of cancer care by unlocking the power of the genome. As the Director of Global Market Access Strategy –Oncology, you will lead global strategies to ensure patients worldwide have access to our transformative oncology testing solutions. Spanning hereditary risk testing, solid and liquid tumor profiling and monitoring, your work will help shape the future of precision oncology. This includes Market Access strategies for emerging oncology testing applications and indications (e.g. WGS, MRD, and early detection).
This is a high-impact, strategic leadership role that requires deep expertise in oncology diagnostics, payer engagement, and global reimbursement landscapes. You will collaborate across regions and functions to shape the value narrative, secure reimbursement, and drive adoption of our technologies in diverse healthcare systems.
Key Responsibilities:
Qualifications:
#LI-REMOTE
The estimated base salary range for the Director, Global Market Access Strategy – Oncology (Remote) role based in the United States of America is: $205,100 - $307,700. Should the level or location of the role change during the hiring process, the applicable base pay range may be updated accordingly. The range reflects long‑term growth in the role; therefore, most candidates are hired between the minimum and middle of the range. Placement depends on experience, skills, location, and internal equity. Additionally, all employees are eligible for one of our variable cash programs (bonus or commission) and eligible roles may receive equity as part of the compensation package. We offer a wide range of benefits as innovative as our work, including access to genomics sequencing, family planning, health/dental/vision, retirement benefits, and paid time off.Illumina develops and sells integrated sequencing systems and the consumables needed to analyze genetic variation and biological function. Its instruments use sequencing-by-synthesis on flow-cell-based platforms, with specialized reagents and library preparation kits that are consumed per run. The company differentiates itself through a broad end-to-end ecosystem, a large installed base that drives repeat purchases, and strategic acquisitions that expand capabilities into multiomics and clinical applications. Its goal is to advance genomic analysis for research and clinical diagnostics to enable personalized medicine and early cancer detection.
Explore more opportunities at Illumina